HOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

Leukemia

Volumn 24, Issue 6, 2010, Pages 1243-1245

  Bazeos, A ^a   Marin, D ^a   Reid, A G ^a   Gerrard, G ^a   Milojkovic, D ^a   May, P C ^a   De Lavallade, H ^a   Garland, P ^a   Rezvani, K ^a   Apperley, J F ^a   Goldman, J M ^a   Foroni, L ^a   Khorashad, J S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; METFORMIN; ORGANIC CATION TRANSPORTER 1; ANTINEOPLASTIC AGENT; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 1; PIPERAZINE DERIVATIVE; POU2F1 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; HEMATOPOIESIS; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; OCTAMER TRANSCRIPTION FACTOR-1; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77954569110     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.86     Document Type: Letter

References (8)

1. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745. (Pubitemid 39564452)
2. Marin D, Bazeos A, Mahon F-X, Eliason L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol; e-pub ahead of print 12 April 2010.
3. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258-264.
4. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133-1134.
5. Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27: 3642-3649.
6. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371-2378.
7. Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517-2525.
8. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273-280.